Abstract:BACKGROUND: A recent outbreak of SARS-CoV-2 infection occurs mainly in China, with rapidly increasing the number of cases (namely COVID-19). Abnormal liver functions are frequently present in these patients, here we aimed to clarify the clinical features of COVID-19-related liver damage to provide some references for the clinical treatment. METHODS: In this retrospective, single-center study, we included all confirmed COVID-19 cases in Shanghai Public Health Clinical Center from January 20 to January 31, 2020. The outcomes were followed up until February 19, 2020. A total of 148 cases were analyzed for clinical features, laboratory parameters (including liver function tests), medications and the length of stay. FINDINGS: Of 148 confirmed SARS-CoV-2-infected patients, 49.3% were females and 50.7% were males. The median age was 50.5 years (interquartile range, 36-64). Patients had clinical manifestations of fever (70.1%), cough (45.3%), expectoration (26.7%) at admission. 75 patients (50.7%) showed abnormal liver functions at admission, characterized by an increased of alt, ast, GGT, AKP. Patients (n = 75) who had elevated liver function index were more likely to have a moderate-high degree fever (44% vs 27.4%; p = 0.035) and significantly present in male patients (62.67% vs 38.36%; p = 0.005). The numbers of CD4+ and CD8+ T cells were significantly lower in abnormal liver function group than those in normal liver function group. There was no statistical difference in prehospital medications between normal and abnormal liver function groups, while the utilization rate of lopinavir/ritonavir after admission was significantly higher in patients with emerging liver injury than that in patients with normal liver functions. Importantly, the emerging abnormal liver functions after admission caused a prolonged length of stay. INTERPRETATION: SARS-CoV-2 may cause the liver function damage and the Lopinavir/ritonavir should be applied carefully for the treatment of COVID-19.

Liver injury in COVID-19: A minireview

Liver Diseases in COVID-19: Etiology, Treatment and Prognosis

Liver diseases in COVID-19: Etiology, treatment and prognosis.

Liver Injury in Patients with COVID-19: A Retrospective Study

Liver Injury in COVID-19: Detection, Pathogenesis, and Treatment

Liver injury in severe COVID-19 infection: current insights and challenges

COVID-19-associated liver injury: Adding fuel to the flame

COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management

Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments

Clinical Features of COVID-19-Related Liver Damage

COVID-19 and Liver Dysfunction: Epidemiology, Association and Potential Mechanisms

Liver injury during highly pathogenic human coronavirus infections

Molecular and Cellular Mechanisms of Liver Dysfunction in COVID-19.

Implications of liver injury in risk-stratification and management of patients with COVID-19

Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease 2019

MECHANISM OF SARS-COV-2 INVASION INTO THE LIVER AND HEPATIC INJURY IN PATIENTS WITH COVID-19

Liver injury in COVID-19: an insight into pathobiology and roles of risk factors

Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications

Pathophysiological mechanisms of liver injury in COVID‐19

Liver Injury Caused by Antiviral Agents for COVID-19

Direct or Collateral Liver Damage in SARS-CoV-2–Infected Patients